Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for MeiraGTx Holdings PLC (MGTX : NSDQ)

• Company Description    MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. Number of Employees: 381

• Price / Volume Information    Yesterday's Closing Price: $7.75 Daily Weekly Monthly 20 Day Moving Average: 381,942 shares Shares Outstanding: 80.45 (millions) Market Capitalization: $623.47 (millions) Beta: 1.34 52 Week High: $8.98 52 Week Low: $4.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 2.51% 2.52% 12 Week -7.41% -11.23% Year To Date 27.26% 12.32%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 450 East 29th Street 14th Floor - NEW YORK,NY 10016 USA ph: 646-860-7985 fax: - investors@meiragtx.com http://www.meiragtx.com

• General Corporate Information    Officers Alexandria Forbes - Chief Executive Officer;President and Director Keith R. Harris - Chairman of the Board and Director Richard Giroux - Chief Financial Officer Ellen Hukkelhoven - Director Lord Mendoza - Director Peer Information MeiraGTx Holdings PLC (CORR.) MeiraGTx Holdings PLC (RSPI) MeiraGTx Holdings PLC (CGXP) MeiraGTx Holdings PLC (BGEN) MeiraGTx Holdings PLC (GTBP) MeiraGTx Holdings PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G59665102 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 80.45 Most Recent Split Date: (:1) Beta: 1.34 Market Capitalization: $623.47 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.57 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 39.13% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 210.42 Price/Cash Flow: - Price / Sales: 16.44 EPS Growth vs. Year Ago Period: 36.84% vs. Previous Quarter: 5.88% Sales Growth vs. Year Ago Period: 1,208.87% vs. Previous Quarter: 91.64% ROE 09/30/25 - - 06/30/25 - -314.44 03/31/25 - -241.05 ROA 09/30/25 - - 06/30/25 - -63.28 03/31/25 - -62.93 Current Ratio 09/30/25 - - 06/30/25 - 0.88 03/31/25 - 1.53 Quick Ratio 09/30/25 - - 06/30/25 - 0.88 03/31/25 - 1.51 Operating Margin 09/30/25 - - 06/30/25 - -413.85 03/31/25 - -483.21 Net Margin 09/30/25 - - 06/30/25 - -415.39 03/31/25 - -484.90 Pre-Tax Margin 09/30/25 - - 06/30/25 - -415.39 03/31/25 - -484.90 Book Value 09/30/25 - - 06/30/25 - 0.04 03/31/25 - 0.41 Inventory Turnover 09/30/25 - - 06/30/25 - 85.28 03/31/25 - 101.49 Debt-to-Equity 09/30/25 - - 06/30/25 - 26.29 03/31/25 - 2.34 Debt-to-Capital 09/30/25 - - 06/30/25 - 96.34 03/31/25 - 70.10

Powered by Zacks Investment Research ©